Scientists pinpoint optimal sedation dose for safer gastroscopy across ages
NCT ID NCT07678411
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This study aims to find the 90% effective dose of tegileridine, a painkiller, when combined with propofol for sedation during painless gastroscopy. Researchers will test different doses in young (18-65) and elderly (65+) adults to see which dose best prevents movement, coughing, or blood pressure changes during the procedure. The goal is to improve sedation safety and effectiveness for both age groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tegileridine combined with propofol
What this could lead to
If successful, this could establish a precise, safer sedation dose for gastroscopy in different age groups, reducing side effects.
What could go wrong
This is a small, early-phase dose-finding study, not a large effectiveness trial. Results may not apply to all patients or procedures.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAINLESS GASTROSCOPY PERIOPERATIVE SEDATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tianmen First People's Hospital, Affiliated Hospital of Wuhan University of Science and Technology
Tianmen, Hubei, 431700, China
Contact Phone: •••-•••-•••• Email: •••••@•••••